Latest Articles about CPHD

Neutral Rating Restated for Cepheid - Analyst Blog

Zacks Equity Research — Mon, 13 May 2013 23:15:57 Z

On May 9, 2013, we reaffirmed our long-term Neutral recommendation on Cepheid ( CPHD ) following strong first-quarter results. While the company continues to record strong quarterly

DexCom Loss Narrower than Est. - Analyst Blog

Zacks Equity Research — Thu, 02 May 2013 22:26:20 Z

DexCom, Inc. ( DXCM ), a player in the glucose monitoring market, reported first quarter 2013 adjusted loss per share of 16 cents, narrower than the Zacks Consensus Estimate of a loss of 17

Huge Earnings Miss By AMED, Guides Low - Analyst Blog

Zacks Equity Research — Wed, 01 May 2013 23:38:01 Z

Home healthcare provider Amedisys ( AMED ) reported net income of $3.9 million or 9 cents per share in the first quarter of 2013, a considerable slide from net income of $8.6 million or

ResMed's Earnings Beat; Revs Lag - Analyst Blog

Zacks Equity Research — Mon, 29 Apr 2013 22:50:33 Z

ResMed Inc. (RMD) posted adjusted earnings per share (EPS) of 59 cents in the third quarter of fiscal 2013, edging past the Zacks Consensus Estimate by a couple of cents. The results were also

Weekly CEO Sells Highlight: SeaCube, Hasbro, Cepheid, Honeywell

alicet236 — Mon, 29 Apr 2013 05:59:59 Z

According to GuruFocus Insider Data , these are the largest CEO sales during the past week: SeaCube Container Leasing Ltd., Hasbro Inc., Cepheid and Honeywell International Inc. SeaCube

Covidien Expands Shiley Offerings - Analyst Blog

Zacks Equity Research — Fri, 19 Apr 2013 23:50:01 Z

International health care products major, Covidien plc ( COV ) has expanded its portfolio of Shiley neonatal and pediatric tracheostomy tubes with the launch of a new offering. The

FDA Nod for Luminex Offering - Analyst Blog

Zacks Equity Research — Fri, 19 Apr 2013 22:10:10 Z

Diagnostic testing technologies company, Luminex Corporation ( LMNX ) has won clearance from the U.S. Food and Drug Administration for its MAGPIX instrument, with its xTAG Gastrointestinal

Cepheid Earnings Beat, Retains Outlook - Analyst Blog

Zacks Equity Research — Fri, 19 Apr 2013 20:13:35 Z

Cepheid ( CPHD ) reported first-quarter 2013 adjusted earnings of 2 cents per share, significantly better than the Zacks Consensus Estimate of loss of 2 cents per share and loss of 10 cents

New Patent for Biolase - Analyst Blog

Zacks Equity Research — Fri, 19 Apr 2013 00:12:15 Z

Recently, dental lasers' manufacturer and distributor, BIOLASE, Inc. ( BIOL ) was awarded a new patent for its non-contact laser hand piece for tissue cutting by the U.S. Patent and

Volcano Corporation Stays Neutral - Analyst Blog

Zacks Equity Research — Thu, 18 Apr 2013 23:12:16 Z

Recently, we have reaffirmed our Neutral recommendation on Volcano Corporation ( VOLC ). Although we are concerned about the company's disappointing fourth quarter 2012 and conservative

Myriad Downgraded to Neutral - Analyst Blog

Zacks Equity Research — Thu, 18 Apr 2013 23:10:46 Z

On Apr 17, we downgraded our recommendation on Myriad Genetics Inc. ( MYGN ) to Neutral from Outperform. Despite the recent healthy growth, the stock is presently out of favor on account of

Encouraging 4Q Prelims for Abiomed - Analyst Blog

Zacks Equity Research — Thu, 18 Apr 2013 22:09:28 Z

Leading cardiac assist devices maker, Abiomed Inc. ( ABMD ), provided encouraging preliminary data for its fourth-quarter 2013 results. The company will report full results on May 2, 2013.

Varian Applies Latest Vitesse - Analyst Blog

Zacks Equity Research — Wed, 17 Apr 2013 23:13:40 Z

Oncology and X-Ray products company Varian Medical Systems ( VAR ) recently revealed that a patient with prostate cancer was the first to receive therapy from the most current edition of

More Backing for HOLX Tomosynthesis - Analyst Blog

Zacks Equity Research — Wed, 17 Apr 2013 23:10:39 Z

Leading player in the women's health market Hologic Inc. ( HOLX ) continues to leap forward with positive data supporting the adoption of its tomosynthesis technology. The company stated

Another Earnings Miss for DGX - Analyst Blog

Zacks Equity Research — Wed, 17 Apr 2013 21:16:35 Z

Leading diagnostic testing company, Quest Diagnostics ( DGX ) reported earnings per share ("EPS") from continuing operations of 72 cents in the first quarter of 2013, down